-
公开(公告)号:US11773372B2
公开(公告)日:2023-10-03
申请号:US17211863
申请日:2021-03-25
Applicant: Yeda Research and Development Co. Ltd.
Inventor: Yair Reisner , Noga Or-Geva , Rotem Gidron Budovsky , Esther Bachar-Lustig , Assaf Lask , Sivan Kagan
IPC: C12N5/0783 , A61K35/17 , A61K39/00 , C12N5/00 , A61K35/12
CPC classification number: C12N5/0637 , A61K35/17 , A61K39/001 , C12N5/0087 , A61K2035/122 , A61K2039/5158 , C12N2501/2307 , C12N2501/2315 , C12N2501/2321 , C12N2502/1121
Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
-
公开(公告)号:US10961504B2
公开(公告)日:2021-03-30
申请号:US16313486
申请日:2017-06-27
Applicant: Yeda Research and Development Co. Ltd.
Inventor: Yair Reisner , Noga Or-Geva , Rotem Gidron Budovsky , Esther Bachar-Lustig , Assaf Lask , Sivan Kagan
IPC: C12N5/0783 , A61K35/17 , A61K39/00 , C12N5/00 , A61K35/12
Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
-